BR112014026649A2 - anticorpo anti-robo4 - Google Patents
anticorpo anti-robo4Info
- Publication number
- BR112014026649A2 BR112014026649A2 BR112014026649A BR112014026649A BR112014026649A2 BR 112014026649 A2 BR112014026649 A2 BR 112014026649A2 BR 112014026649 A BR112014026649 A BR 112014026649A BR 112014026649 A BR112014026649 A BR 112014026649A BR 112014026649 A2 BR112014026649 A2 BR 112014026649A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- present disclosure
- angiogenesis
- robo4
- pharmaceutical composition
- Prior art date
Links
- 230000000694 effects Effects 0.000 abstract 4
- 230000003527 anti-angiogenesis Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 abstract 1
- 101150030763 Vegfa gene Proteins 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000016784 immunoglobulin production Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
resumo patente de invenção: "anticorpo anti-robo4". a presente invenção refere-se a um anticorpo que possui uma atividade antiangiogênese. mais especificamente, a presente divulgação refere-se a um anticorpo contra robo4 e uma composição farmacêutica contendo o anticorpo. um objetivo da presente divulgação é fornecer um anticorpo antirobo4 tendo um efeito antiangiogênese, uma composição farmacêutica ou similar, que compreende o anticorpo, um método para suprimir a angiogênese utilizando o anticorpo, etc.. outro objetivo da presente divulgação é fornecer um método para a produção do anticorpo. solução: o anticorpo da presente divulgação ativa o sinal a jusante de robo4 e possui uma atividade supressora contra a migração celular induzida pelo vegf ou bfgf. o anticorpo da presente divulgação também apresenta um efeito antiangiogênese em modelos in vivo. assim, o problema foi resolvido. 22612582v1 1/1 22612582v1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012103929A JP2013230115A (ja) | 2012-04-27 | 2012-04-27 | 抗ｒｏｂｏ４抗体 |
| JP2013011042A JP2014141434A (ja) | 2013-01-24 | 2013-01-24 | 抗ｒｏｂｏ４抗体 |
| PCT/IB2013/053312 WO2013160879A1 (en) | 2012-04-27 | 2013-04-26 | Anti-robo4-antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014026649A2 true BR112014026649A2 (pt) | 2017-07-18 |
Family
ID=48670623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014026649A BR112014026649A2 (pt) | 2012-04-27 | 2013-04-26 | anticorpo anti-robo4 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9683040B2 (pt) |
| EP (1) | EP2841457B1 (pt) |
| JP (2) | JP5897205B2 (pt) |
| KR (2) | KR101950898B1 (pt) |
| CN (1) | CN104768973B (pt) |
| AU (1) | AU2013254313B2 (pt) |
| BR (1) | BR112014026649A2 (pt) |
| CA (1) | CA2868074A1 (pt) |
| CO (1) | CO7111295A2 (pt) |
| DK (1) | DK2841457T3 (pt) |
| ES (1) | ES2733434T3 (pt) |
| HK (1) | HK1207093A1 (pt) |
| IN (1) | IN2014DN07799A (pt) |
| MX (1) | MX356749B (pt) |
| MY (1) | MY166821A (pt) |
| NZ (1) | NZ629291A (pt) |
| PH (1) | PH12014502382B1 (pt) |
| PL (1) | PL2841457T3 (pt) |
| RU (1) | RU2682451C2 (pt) |
| SG (1) | SG11201405718QA (pt) |
| TW (1) | TWI606065B (pt) |
| WO (1) | WO2013160879A1 (pt) |
| ZA (1) | ZA201406235B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013254313B2 (en) * | 2012-04-27 | 2017-03-30 | Daiichi Sankyo Company, Limited | Anti-ROBO4-antibody |
| TWI836305B (zh) | 2015-09-24 | 2024-03-21 | 日商第一三共股份有限公司 | 抗ｇａｒｐ抗體及其製造方法及用途 |
| JPWO2018070390A1 (ja) * | 2016-10-12 | 2019-08-22 | 第一三共株式会社 | 抗ｒｏｂｏ４抗体と他剤を含む組成物 |
| KR20210070643A (ko) | 2019-12-05 | 2021-06-15 | 김명배 | 자체 발전 웨어러블 다리 |
| WO2023156437A1 (en) | 2022-02-16 | 2023-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer |
| CN117384290B (zh) * | 2023-12-11 | 2024-04-09 | 苏州因特药物研发有限公司 | 人源robo1结合分子及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
| ATE275198T1 (de) | 1991-12-02 | 2004-09-15 | Medical Res Council | Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken. |
| EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
| AU690171B2 (en) | 1993-12-03 | 1998-04-23 | Medical Research Council | Recombinant binding proteins and peptides |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
| ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| CN102311986B (zh) | 2000-10-06 | 2015-08-19 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| WO2002036771A2 (en) | 2000-11-06 | 2002-05-10 | Cancer Research Technology Limited | Imaging, diagnosis and treatment of disease |
| JP4583638B2 (ja) * | 2001-03-15 | 2010-11-17 | 独立行政法人科学技術振興機構 | アセチルリジン認識モノクローナル抗体及びその製造方法 |
| US20060160729A1 (en) | 2002-06-27 | 2006-07-20 | Li Dean Y | Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| EP1565491B1 (en) * | 2002-11-20 | 2010-03-31 | Cancer Research Technology Limited | Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition of angiogenesis |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| JP2010512327A (ja) | 2006-12-11 | 2010-04-22 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | 病的血管形成および脈管透過性の処置用の組成物および方法 |
| EP2468776A3 (en) | 2007-02-09 | 2012-11-14 | Genentech, Inc. | Anti-Robo4 antibodies and uses therefor |
| TWI480050B (zh) * | 2009-02-10 | 2015-04-11 | Daiichi Sankyo Co Ltd | 抗－ｍｓｔ１ｒ抗體及其用途 |
| AU2013254313B2 (en) * | 2012-04-27 | 2017-03-30 | Daiichi Sankyo Company, Limited | Anti-ROBO4-antibody |
-
2013
- 2013-04-26 AU AU2013254313A patent/AU2013254313B2/en not_active Ceased
- 2013-04-26 IN IN7799DEN2014 patent/IN2014DN07799A/en unknown
- 2013-04-26 TW TW102115219A patent/TWI606065B/zh not_active IP Right Cessation
- 2013-04-26 US US14/397,210 patent/US9683040B2/en active Active
- 2013-04-26 SG SG11201405718QA patent/SG11201405718QA/en unknown
- 2013-04-26 NZ NZ629291A patent/NZ629291A/en not_active IP Right Cessation
- 2013-04-26 KR KR1020147029492A patent/KR101950898B1/ko active IP Right Grant
- 2013-04-26 BR BR112014026649A patent/BR112014026649A2/pt not_active Application Discontinuation
- 2013-04-26 MY MYPI2014703067A patent/MY166821A/en unknown
- 2013-04-26 KR KR1020197004552A patent/KR20190020838A/ko not_active Application Discontinuation
- 2013-04-26 WO PCT/IB2013/053312 patent/WO2013160879A1/en active Application Filing
- 2013-04-26 PL PL13730645T patent/PL2841457T3/pl unknown
- 2013-04-26 EP EP13730645.2A patent/EP2841457B1/en active Active
- 2013-04-26 ES ES13730645T patent/ES2733434T3/es active Active
- 2013-04-26 CA CA2868074A patent/CA2868074A1/en not_active Abandoned
- 2013-04-26 RU RU2014147616A patent/RU2682451C2/ru not_active IP Right Cessation
- 2013-04-26 CN CN201380019999.8A patent/CN104768973B/zh not_active Expired - Fee Related
- 2013-04-26 DK DK13730645.2T patent/DK2841457T3/da active
- 2013-04-26 JP JP2015507659A patent/JP5897205B2/ja active Active
- 2013-04-26 MX MX2014012351A patent/MX356749B/es active IP Right Grant
-
2014
- 2014-08-25 ZA ZA2014/06235A patent/ZA201406235B/en unknown
- 2014-10-24 PH PH12014502382A patent/PH12014502382B1/en unknown
- 2014-10-27 CO CO14236457A patent/CO7111295A2/es unknown
-
2015
- 2015-08-10 HK HK15107712.5A patent/HK1207093A1/xx not_active IP Right Cessation
- 2015-12-11 US US14/966,292 patent/US9562096B2/en active Active
-
2016
- 2016-03-01 JP JP2016038918A patent/JP6267733B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014026649A2 (pt) | anticorpo anti-robo4 | |
| EA201791299A1 (ru) | Микроинкапсулированные композиции каннабиноидов | |
| BR112015029969A2 (pt) | tratamento de câncer usando moduladores de isoformas quinase pi3 | |
| BR112014029762A2 (pt) | composição contendo n-metil-n-acilglucamina | |
| BR112014027204A2 (pt) | conjugados d ácido graxo de estatina e agonistas fxr; composições e método de usos | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| BR112014029286A2 (pt) | composição cosmética sólida, processo para sua produção, produto e método cosmético | |
| BR112017004231A2 (pt) | processo para produzir um precipitado estável enriquecido em ficobiliproteínas | |
| BR112016013194A2 (pt) | Composições de higiene oral compreendendo carbonato de cálcio e sílica | |
| BR112015031417A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem | |
| BR112015017251A2 (pt) | composições farmacêuticas compreendendo doadores de nitroxil | |
| BR112014020113A8 (pt) | Composições farmacêuticas e método para diminuir a frequência de micção | |
| ZA201508750B (en) | Compounds of '3-(5-sustituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester', process and applications thereof | |
| BR112017004246A2 (pt) | mancal simples ou parte do mesmo, método para a sua produção e uso de uma liga de cucrzr como um material de mancal simples | |
| BR112016028518A2 (pt) | composições farmacêuticas que compreendem dgla e uso do mesmo | |
| BR112016013316A8 (pt) | método para a produção de furfural e uso de ácido metanossulfônico | |
| FR3009956B1 (fr) | Composition hydratante sous forme d’emulsion huile-dans-eau ; procede de soin hydratant | |
| BR112015022513A2 (pt) | produto e método para tratamento de diarreia | |
| BR112014016234A2 (pt) | composições nutricionais estabilizadas incluindo amido | |
| FR3002454B1 (fr) | Composition immunogene sous forme d'emulsion | |
| BR112017020053A2 (pt) | novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo | |
| BR112015017432A2 (pt) | métodos para o tratamento de indicações cardiovasculares | |
| BR112015028025A2 (pt) | composição farmacêutica adaptada para administração oral e regime de tratamento para o controle de insuficiência adrenal | |
| BR112015004494A2 (pt) | célula de fluxo de permeabilidade e sistema de condutância hidráulica | |
| BR112015004348A2 (pt) | célula de fluxo de permeabilidade e sistema de condutância hidráulica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |